Effect of β-blockers on free radical-induced cardiac contractile dysfunction

Circulation

Volumn 100, Issue 4, 1999, Pages 346-353

  Flesch, M ^a,b   Maack, C ^a   Cremers, B ^a   Baumer A T ^a   Sudkamp M ^a   Bohm M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Universität zu Köln ^*  (Germany)

Author keywords

Contractility; Free radicals; Heart failure; Receptors, adrenergic, beta

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BM 910228; CARVEDILOL; DRUG METABOLITE; FREE RADICAL; HYDROGEN PEROXIDE; HYDROXYL RADICAL; METOPROLOL; NITRILOTRIACETIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FORCE; HEART; HEART CONTRACTION; HEART FAILURE; HUMAN; HUMAN TISSUE; INOTROPISM; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DENSITY; SARCOPLASMIC RETICULUM;

EID: 0033609455     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.4.346     Document Type: Article

References (38)

1. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol. 1998;31:1352-1356.
2. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900-905.
3. Bolli R. Mechanisms of myocardial "stunning." Circulation. 1990;82: 723-738.
4. 2+ activation of contraction as a consequence of reperfusion-induced calcium overload in ferret hearts. J Clin Invest. 1987;79:950-961.
5. Josephson RA, Silverman HS, Lakatta EG, Stern MD, Zweier JL. Study of the mechanisms of hydrogen peroxide and hydroxyl free radical induced cellular injury and calcium overload in cardiac myocytes. J Biol Chem. 1991;266:2354-2361.
6. 2+ responsiveness and altered diastolic function in intact ventricular muscle. Circ Res. 1995;76: 1036-1048.
7. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993; 342:1441-1446.
8. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the cardiac insufficiency bisoprolol study (CIBIS). Circulation. 1994;90:1765-1773.
9. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
10. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
11. Feldman AM, Gates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, Van Dop C. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest. 1998;82:189-197.
12. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94: 2817-2825.
13. Yue TL, Cheng H-Y, Lysko P, McKenna PJ, Feuerstein R, Gu J-L, Lysko KA, Davis LL, Feuerstein G. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.
14. Feuerstein GZ, George P, Ruffolo RR. Carvedilol update, III: rationale for use in congestive heart failure. Drugs Today. 1995;31:307-326.
15. Yue TL, Ma XL, Wng X, Romanic AM, Liu G-L, Louden C, Gu J-L, Kumar S, Poste G, Ruffolog RR, Feuerstein GZ. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res. 1998;82:166-174.
16. Maulik N, Yoshida T, Das DK. Oxidative stress developed during the reperfusion of ischemic myocardium induces apoptosis. Free Radic Biol Med. 1998;24:869-875.
17. Belch JJF, Bridges AB, Scott N, Chopra M. Oxygen derived free radicals and congestive heart failure. Br Heart J. 1991;65:245-248.
18. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski W, Reed JC, Anversa P. Apoptosis in the failing human heart. N Engl J Med. 1997;336: 1131-1141.
19. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FE, Hajjar RJ, Schmidt U, Semigran MJ, Dee GW, Khaw BA. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 1996;335:1182-1189.
20. Bolli R, Jeroudi MO, Patel BS, Aruoma OI, Halliwell B, Lai EK, McCay PB. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion: evidence that myocardial "stunning" is a manifestation of reperfusion injury. Circ Res. 1989;65:607-622.
21. Farber NE, Vercellotti GM, Jacob HS, Pieper GM, Gross GJ. Evidence for a role of iron-catalyzed oxidants in functional and metabolic stunning in the canine heart. Circ Res. 1988;63:351-360.
22. Blaustein AS, Schine L, Brooks WW, Fanburg BL, Bing OH. Influence of exogenously generated oxidant species on myocardial function. Am J Physiol. 1986;250:H595-H599.
23. Kramer JH, Weglicki B. A hydroxylated analog of the β-adrenoceptor blocker antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts. Free Radic Biol Med. 1996;21:813-825.
24. Böhm M, Ettelbrück S, Flesch M, van Gielst WH, Knorr A, Maack C, Pinto YM, Paul M, Teisman ACH, Zolk O. β-Adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy. Cardiovasc Res. 1998;40:146-155.
25. 50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099-3108.
26. 2+ exchanger in the failing human heart. Circulation. 1996;94:992-1002.
27. 2+, adenine nucleotide and calmodulin. J Biol Chem. 1987;262: 3065-3073.
28. Sitsapesan R, Williams AJ. Mechanisms of caffeine activation of single calcium release channels of sheep cardiac sarcoplasmic reticulum. J Physiol. 1990;423:425-439:
29. Kyte J. Purification of the sodium-and potassium-dependent adenosine triphosphate from canine renal medulla. J Biol Chem. 1972;246: 4157-4165.
30. 2+-ATPaSe function by direct attack on the ATP binding site. Circ Res. 1997;80:76-81.
31. Fabiato A. Computer programs for calculating total from specified free or free from specified total ionic concentrations in aqueous solutions containing multiple metals and ligands. Methods Enzymol. 1988;157: 378-417.
32. Coretti MC, Koretsune Y, Kusuoka H, Chacko VP, Zweier JL, Marban E. Glycolytic inhibition and calcium overload as consequences of exogenously generated free radicals in rabbit hearts. J Clin Invest. 1991;88: 1014-1025.
33. Zweier JL, Kuppusamy P, Williams R, Rayburn BK, Smith D, Weissfeldt ML, Flaberty JT. Measurement and characterization of postischemic free radical generation in the isolated perfused heart. J Biol Chem. 1989;264: 18890-18895.
34. Garlick PB, Davies MJ, Hearse DJ, Slater TF. Direct detection of free radicals in the reperfused rat heart using electron spin resonance spectroscopy. Circ Res. 1987;61:757-760.
35. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992;85:1743-1750.
36. 2+-ATPase in failing and nonfailing human myocardium. Circ Res. 1994;75:434-442.
37. 2+ handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation. 1995;92:1169-1178.
38. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;21:1468-1475.